Oncolytic Virus Therapy Passes Early Efficacy Tests in Glioma Subtypes

Lisa Astor
Published: Sunday, Jan 07, 2018
Clark C. Chen, MD, PhD

Clark C. Chen, MD, PhD
A2-step oncolytic virus has demonstrated promising signals against aggressive forms of brain cancers, including recurrent glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), in early clinical studies, according to findings presented at the 2017 AACRNCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

“This approach is fundamentally not just a gene therapy but also an immune therapy that combines the efficacy of both approaches,” said Chen.

Early Clinical Findings

Three phase I studies were conducted to test the safety and tolerability of Toca 511 and Toca FC in 127 total patients with recurrent high-grade gliomas.1 The first dose-escalating study looked at 56 patients who had undergone surgical resection of their brain tumor (NCT01470794), and Chen focused on safety and efficacy results from this study in his presentation. In the second study, the tumor was infused into 54 patients with unresectable tumors (NCT01156584), and the third focused on neoadjuvant intravenous administration of the virus in patients with grade III/IV glioma (NCT01985256).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication